Case Number 12098
Request Date 03/09/2026
Completion Date 25/09/2026

 

Details of the Request

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

  • Abatacept [Orencia]
  • Adalimumab [Humira]
  • Adalimumab Biosimilars
  • Apremilast [Otezla]
  • Apremilast [Generic]
  • Baricitinib [Olumiant]
  • Bimekizumab [Bimzelx]
  • Certolizumab [Cimzia]
  • Etanercept [Enbrel]
  • Etanercept Biosimilars
  • Filgotinib [Jyseleca]
  • Golimumab [Simponi]
  • Golimumab Biosimilar
  • Guselkumab [Tremfya]
  • Infliximab [Remicade]
  • Infliximab Biosimilars
  • Ixekizumab [Taltz]
  • Risankizumab [Skyrizi]
  • Rituximab [MabThera]
  • Rituximab Biosimilars
  • Sarilumab [Kevzara]
  • Secukinumab [Cosentyx]
  • Tocilizumab [Ro Actemra]
  • Tocilizumab Biosimilars
  • Tofacitinib [Xeljanz]
  • Upadacitinib [Rinvoq]
  • Ustekinumab [Stelara]
  • Ustekinumab Biosimilar

 

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:

  • Adalimumab [Humira]
  • Adalimumab Biosimilars
  • Bimekizumab [Bimzelx]
  • Certolizumab [Cimzia]
  • Etanercept [Enbrel]
  • Etanercept Biosimilars
  • Golimumab [Simponi]
  • Golimumab Biosimilar
  • Infliximab [Remicade]
  • Infliximab Biosimilars
  • Ixekizumab [Taltz]
  • Secukinumab [Cosentyx]
  • Tofacitinib [Xeljanz]
  • Upadacitinib [Rinvoq]

 

Details of the Response

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

  • Abatacept [Orencia] = 35
  • Adalimumab [Humira] = 27
  • Adalimumab Biosimilars = 343
  • Apremilast [Otezla] = 0
  • Apremilast [Generic] = 0
  • Baricitinib [Olumiant] = 7
  • Bimekizumab [Bimzelx] = 1
  • Certolizumab [Cimzia] = 34
  • Etanercept [Enbrel] = 1
  • Etanercept Biosimilars = 119
  • Filgotinib [Jyseleca] = 12
  • Golimumab [Simponi] = 7
  • Golimumab Biosimilar = 0
  • Guselkumab [Tremfya] = 3
  • Infliximab [Remicade] = 0
  • Infliximab Biosimilars = 3
  • Ixekizumab [Taltz] = 0
  • Risankizumab [Skyrizi] = 2
  • Rituximab [MabThera] = 0
  • Rituximab Biosimilars = 28
  • Sarilumab [Kevzara] = 0
  • Secukinumab [Cosentyx] = 53
  • Tocilizumab [Ro Actemra] = 39
  • Tocilizumab Biosimilars = 0
  • Tofacitinib [Xeljanz] = 3
  • Upadacitinib [Rinvoq] = 12
  • Ustekinumab [Stelara] = 0
  • Ustekinumab Biosimilar = 7

 

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:

  • Adalimumab [Humira] = 3
  • Adalimumab Biosimilars = 30
  • Bimekizumab [Bimzelx] = 0
  • Certolizumab [Cimzia] = 2
  • Etanercept [Enbrel] = 0
  • Etanercept Biosimilars = 6
  • Golimumab [Simponi] = 1
  • Golimumab Biosimilar = 0
  • Infliximab [Remicade] = 0
  • Infliximab Biosimilars = 1
  • Ixekizumab [Taltz] = 0
  • Secukinumab [Cosentyx] = 9
  • Tofacitinib [Xeljanz] = 0
  • Upadacitinib [Rinvoq] = 2

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.